Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
Open accessThe DOI matches its Crossref record; 155 of the 156 references it cites were found in a registry or an index, and 1 are not checked yet; 37 of the 185 sources its claims cite were checked for support.
Abstract
Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8.2 months in RAS wild-type (WT) mCRC patients. Unfortunately, resistance to targeted therapy impairs clinical use and efficiency. The mechanisms of resistance refer to intrinsic and extrinsic alterations of tumours. Multiple therapeutic strategies have been investigated extensively to overcome resistance to anti-EGFR mAbs. The intrinsic mechanisms include EGFR ligand overexpression, EGFR alteration,RAS/RAF/PI3K gene mutations, ERBB2/MET/IGF-1R activation, metabolic remodelling, microsatellite instability and autophagy. For intrinsic mechanisms, therapies mainly cover the following: new EGFR-targeted inhibitors, a combination of multitargeted inhibitors, and metabolic regulators. In addition, new cytotoxic drugs and small molecule compounds increase the efficiency of cetuximab. Extrinsic alterations mainly disrupt the tumour microenvironment, specifically immune cells, cancer-associated fibroblasts (CAFs) and angiogenesis. The directions include the modification or activation of immune cells and suppression of CAFs and anti-VEGFR agents. In this review, we focus on the mechanisms of resistance to anti-EGFR monoclonal antibodies (anti-EGFR mAbs) and discuss diverse approaches to reverse resistance to this therapy in hopes of identifying more mCRC treatment possibilities.
Verified 2026-10-06 · 1 reference not checked yet
Overview
CoChat Summary
TL;DR
This review summarizes intrinsic and extrinsic mechanisms of resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer and discusses preclinical and clinical strategies to reverse that resistance. It emphasizes that resistance is driven by genetic alterations, compensatory signaling, metabolic remodeling, immune microenvironment changes, CAFs, and angiogenesis, with combination and multitargeted approaches showing the most promise.
Key findings
- Anti-EGFR mAbs benefit only a subset of mCRC patients: cetuximab plus FOLFIRI reduced progression risk by 15% and increased OS by 8.2 months in KRAS WT mCRC versus FOLFIRI alone, but clinical benefit in responders lasts only 8–10 months, and approximately 80% of responders develop resistance.
- Intrinsic resistance mechanisms include EGFR ligand overexpression, EGFR extracellular domain mutations (e.g., G465R, G465E, S468R, S492R), RAS/RAF/PI3K pathway mutations, ERBB2/MET/IGF-1R activation, metabolic remodeling, microsatellite instability, autophagy, CSCs, and EMT.
- Reversal strategies include new anti-EGFR antibodies (necitumumab, Sym004, GC1118, MM-151), multitargeted inhibitors, metabolic regulators, immune therapies, CAF suppression, and antiangiogenic agents. Notable reported results include encorafenib + binimetinib + cetuximab in BRAF V600E mCRC (ORR 26% vs 2%; mOS 9.0 vs 5.4 months), capmatinib + gefitinib in MET-amplified disease (ORR 47%), and tivantinib + cetuximab (ORR 9.8%, mPFS 2.6 months, mOS 9.2 months).
- Extrinsic resistance involves impaired ADCC, dysfunctional NK/T cells, CAF-secreted growth factors, and angiogenesis; avelumab + cetuximab in RAS WT acquired resistance gave mPFS 3.6 months and mOS 11.6 months, while regorafenib + cetuximab produced partial response in 1/17 and stable disease in 7/17 patients.
Methods
- Narrative review of published literature on mechanisms of resistance to anti-EGFR mAbs in mCRC and strategies to reverse resistance.
- Synthesizes preclinical and clinical evidence, including two summary tables: Table 1 for clinical trials and Table 2 for preclinical studies.
- No primary experimental data, systematic search strategy, or meta-analysis is described.
Limitations
- The paper does not state formal limitations.
- Evident from the text: as a review, it provides no new primary data, and conclusions depend on cited studies that include small, early-phase, case-report, and preclinical evidence.
- Evident from the text: several strategies show conflicting or negative results (e.g., vemurafenib studies, PX-866 plus cetuximab, selumetinib plus cetuximab, dalotuzumab/IMC-A12), and the paper notes that more clinical studies are needed for MEK inhibitors, new anti-EGFR mAbs, and cytotoxic agents before clinical application.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
25 Valid · 2 Not valid · 105 Not checked · 21 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“EGFR somatic sequence changes, including G465R, G465E, S468R and S492R, located at the extracellular domains (ECDs) of the EGFR-mAb interaction interface, confer resistance to cetuximab and panitumumab by preventing mAb binding [10, 67, 68].”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies > EGFR ligands and EGFR
What the sources say
- Partly supportedcites [10] Bertotti A Papp E Jones S Adleff V Anagnostou V Lupo B Sausen M Phallen J Hruban CA Tokheim C The genomic landscape of response to EGFR blockade in colorectal cancer Nature. 2015 526 7572 263 267 10.1038/nature14969 26416732 PMC4878148 sourceExperimental — accuracy not yet measured
The paper’s discussion of EGFR ectodomain alterations and Extended Data Figure 2 identify G465R and G465E at the antibody-binding interface and link them to cetuximab resistance; it also reports poor panitumumab sensitivity for G465E tumorgrafts. But the paper says S492R-altered tumors remain sensitive to panitumumab, does not identify S468R in the passages retrieved, and describes impaired binding as a structural inference rather than demonstrating prevention of binding for all four changes. No page numbers are provided in our copy. (LLM, conf=0.90)
- Partly supportedcites [67] Van Emburgh BO Arena S Siravegna G Lazzari L Crisafulli G Corti G Mussolin B Baldi F Buscarino M Bartolini A Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer Nat Commun 2016 7 13665 10.1038/ncomms13665 27929064 PMC5155160 sourceExperimental — accuracy not yet measured
The introductory passage says EGFR extracellular-domain variants impair anti-EGFR antibody binding, and the Discussion identifies mutations in the antibody-binding site as a resistance mechanism. The Results identify S492R in cells exposed to cetuximab. Our copy does not identify G465R, G465E, or S468R, or establish that each listed change prevents binding of both cetuximab and panitumumab. (LLM, conf=0.85)
- Disputedcites [68] Price T Ang A Boedigheimer M Kim TW Li J Cascinu S Ruff P Satya SA Thomas A Tjulandin S Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy Cancer Biol Ther 2020 21 10 891 898 10.1080/15384047.2020.1798695 33026965 PMC7583702 sourceExperimental — accuracy not yet measured
The Results (In vitro receptor binding and activity; page unavailable) show that panitumumab, but not cetuximab, bound to and inhibited S492R mutant EGFR. Thus the claim that S492R prevents binding and confers resistance to both antibodies contradicts this paper. The Discussion mentions G465R resistance to cetuximab, but the retrieved passages do not establish the claimed effects of G465E or S468R. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The hotspot BRAF V600E mutation at codon 600 of exon 15 increases the activity of BRAF kinase by 130- to 700-fold [26, 93–95].”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies > Compensatory feedback loop signalling
What the sources say
- Not checked yetcites [26] Shinozaki E Yoshino T Yamazaki K Muro K Yamaguchi K Nishina T Yuki S Shitara K Bando H Mimaki S Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the biomarker research for anti-EGFR monoclonal antibodies by comprehensive Cancer genomics (BREAC) study Br J Cancer 2017 117 10 1450 1458 10.1038/bjc.2017.308 28972961 PMC5680457 source
- Could not verifycites [93] Vinagre J Almeida A Populo H Batista R Lyra J Pinto V Coelho R Celestino R Prazeres H Lima L Frequency of TERT promoter mutations in human cancers Nat Commun 2013 4 2185 10.1038/ncomms3185 23887589 sourceExperimental — accuracy not yet measured
The Results section reports the presence of BRAF V600E in melanomas, but does not discuss its effect on BRAF kinase activity. Searches for exon 15, codon 600, and a 130- to 700-fold activity increase found no passage addressing those parts of the claim; page numbers were unavailable in our copy. (LLM, conf=0.76)
- Not checked yetcites [94] Pakneshan S Salajegheh A Smith RA Lam AK Clinicopathological relevance of BRAF mutations in human cancer Pathology. 2013 45 4 346 356 10.1097/PAT.0b013e328360b61d 23594689 source
- Disputedcites [95] Davies H Bignell GR Cox C Stephens P Edkins S Clegg S Teague J Woffendin H Garnett MJ Bottomley W Mutations of the BRAF gene in human cancer Nature. 2002 417 6892 949 954 10.1038/nature00766 12068308 sourceExperimental — accuracy not yet measured
The kinase assay in “letters to nature” (p. 3) reports that V599E BRAF had about 10.7-fold the basal kinase activity of wild-type BRAF, not 130- to 700-fold. The same page reports a 70- to 138-fold increase in cell transformation, which is a different measure from kinase activity. Our copy calls the mutation V599E. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Mutations in exons 2, 3 and 4 of KRAS and exons 2, 3, and 4 of NRAS are powerful predictors for cetuximab and panitumumab response in mCRC [81, 82].”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies > Compensatory feedback loop signalling
What the sources say
- Partly supportedcites [81] Bokemeyer C Köhne CH Ciardiello F Lenz HJ Heinemann V Klinkhardt U Beier F Duecker K van Krieken JH Tejpar S FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer Eur J Cancer 2015 51 10 1243 1252 10.1016/j.ejca.2015.04.007 25937522 PMC7508202 sourceExperimental — accuracy not yet measured
The Introduction reports poorer outcomes with KRAS exon 2 mutations for both cetuximab and panitumumab and cites evidence linking other RAS mutations to poorer panitumumab outcomes. But this paper directly studies cetuximab, not panitumumab, and its Results say the small subgroup with other RAS mutations did not permit a formal assessment of predictive effects; calling mutations across all the listed exons “powerful predictors” overstates its findings. Page numbers are not available in our copy. (LLM, conf=0.88)
- Partly supportedcites [82] Blons H Emile JF Le Malicot K Julié C Zaanan A Tabernero J Mini E Folprecht G Van Laethem JL Thaler J Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset Ann Oncol 2014 25 12 2378 2385 10.1093/annonc/mdu464 25294886 sourceExperimental — accuracy not yet measured
The Introduction (p. 2) says KRAS status predicts resistance to EGFR inhibitors in metastatic colorectal cancer. It does not establish the claimed predictive value for KRAS and NRAS mutations across exons 2, 3, and 4, or specifically address response to both cetuximab and panitumumab; the Discussion (p. 5) describes testing KRAS exon 2 and BRAF mutations for prognosis in stage III disease. (LLM, conf=0.88)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Gene mutations downstream of the EGFR signalling pathway, including RAS/RAF/MEK and PI3K/AKT/mTOR, significantly contribute to drug resistance [9–11].”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Background
What the sources say
- Not checked yetcites [9] Karapetis CS Khambata-Ford S Jonker DJ O'Callaghan CJ Tu D Tebbutt NC Simes RJ Chalchal H Shapiro JD Robitaille S K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 2008 359 17 1757 1765 10.1056/NEJMoa0804385 18946061 source
- Supportedcites [10] Bertotti A Papp E Jones S Adleff V Anagnostou V Lupo B Sausen M Phallen J Hruban CA Tokheim C The genomic landscape of response to EGFR blockade in colorectal cancer Nature. 2015 526 7572 263 267 10.1038/nature14969 26416732 PMC4878148 source
The Abstract (Results passage) states that in KRAS wild-type CRC tumorgrafts, alterations in all genes known to be involved in EGFR therapeutic resistance — NRAS, BRAF V600E, MET, ERBB2, plus PIK3CA exon 20 and PTEN truncating/deletion alterations — were detected in cetuximab-resistant tumors, and that 'the enrichment of mutations in these pathways in the resistant tumorgrafts was statistically significant (p<0.001)' and 'alterations in any of these members may be sufficient to render cells insensitive to EGFR inhibition'. Extended Data Fig. 1 is titled 'EGFR signaling pathway genes involved in cetuximab resistance or sensitivity' and depicts members of the RAS and PI3K pathways, while Extended Data Fig. 4 shows ectopic expression of resistance-associated mutations (EGFR G465E, MAP2K1 K57N) inducing cetuximab resistance — supporting a causal contribution of RAS/RAF/MEK and PI3K pathway mutations to anti-EGFR antibody resistance. The pathway naming 'PI3K/AKT/mTOR' is a generic label; our copy documents PIK3CA/PTEN (and AKT signalling via IRS2) rather than MTOR mutations, which does not weaken the attributed point. (LLM, conf=0.85)
- Not checked yetcites [11] De Roock W Claes B Bernasconi D De Schutter J Biesmans B Fountzilas G Kalogeras KT Kotoula V Papamichael D Laurent-Puig P Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol. 2010 11 8 753 762 10.1016/S1470-2045(10)70130-3 20619739 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Progression-free survival (PFS) and OS of patients taking necitumumab plus mFOLFOX6 were comparable to those of the cetuximab and FOLFOX regimens [21].”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies > EGFR ligands and EGFR
What the sources say
- Supportedcites [21] Elez E Hendlisz A Delaunoit T Sastre J Cervantes A Varea R Chao G Wallin J Tabernero J Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer Br J Cancer 2016 114 4 372 380 10.1038/bjc.2015.480 26766738 PMC4815776 source
The Discussion explicitly states that OS and PFS with necitumumab plus mFOLFOX6 were comparable with those reported in previous studies of cetuximab combined with FOLFOX regimens. This is a cross-trial comparison, not a head-to-head finding. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
106 more claims · 17 with their cited sources checked
Create a free account to see all 153 claims and to verify the 148 references still open.
- Probably not a substantial claim. 6
- It may state two separate claims as one. 38
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Progressive disease following anti-EGFR therapy may result from acquired resistance [45,46], which may result from any one of several causes [47].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies
“| Immunity therapy | CAFs | BLU9931 | Cell | Unselected | BLU9931 + cetuximab VS cetuximab | Sensitive VS insensitive | [58] |”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Extrinsic mechanisms of resistance to targeted therapy and related strategies > CAFs and inhibitors
“The combination of BLU9931,an FGFR4 inhibitor, with cetuximab presented profound antitumour activity compared to cetuximab alone [57]. Regorafenib, a multikinase inhibitor targeting FGFR, VEGF and PDGFR-β, was found to overcome cetuximab resistance in GEO-CR and SW48-CR cells in vitro and in vivo [58].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies
“| MET inhibitors | MET | Tivantinib | Phase II | mCRC | KRAS mutation | Tivantinib + cetuximab | ORR: 9.8%, mPFS: 2.6m,mOS:9.2m | [33] |”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > References
“33. Rimassa L Bozzarelli S Pietrantonio F Cordio S Lonardi S Toppo L Zaniboni A Bordonaro R Di Bartolomeo M Tomasello G Phase II study of Tivantinib and Cetuximab in patients with KRAS wild-type metastatic colorectal Cancer with acquired resistance to EGFR inhibitors and emergence of MET overexpression:”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies
“| MET inhibitors | MET | Capmatinib | Phase II | mCRC | MET amplification | Capmatinib + gefitinib | ORR: 47% | [34] |”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > References
“34. Wu YL Zhang L Kim DW Liu X Lee DH Yang JC Ahn MJ Vansteenkiste JF Su WC Felip E Phase Ib/II study of Capmatinib (INC280) plus Gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung Cancer”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies
“| New anti-EGFR mAbs | EGFR ECD | Sym004 | Phase I | mCRC | KRAS WT | Sym004 or investigator’s choice | mOS: 12.8m VS 7.3m | [22] |”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies > EGFR ligands and EGFR
“A multicentre, phase 2 clinical trial further confirmed that Sym004 improved the OS of anti-EGFR-refractory mCRC by 5.5 months [22].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > Intrinsic mechanisms of resistance to targeted therapy and related strategies
“| IGF-1R inhibitors | IGF-1R | IMC-A12 | Phase II | mCRC | Unselected | IMC-A12 + cetuximab VS IMC-A12 | Non response | [36] |”
§ Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies > References
“36. Sclafani F Kim TY Cunningham D Kim TW Tabernero J Schmoll HJ Roh JK Kim SY Park YS Guren TK A randomized phase II/III study of Dalotuzumab in combination with Cetuximab and irinotecan”
2 more findings
Create a free account to see every finding of this check.
Citations
Cites
1 retracted
Targeting CD137 enhances the efficacy of cetuximab
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73014 · Cited by 160
RetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
RAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939
Frequency of TERT promoter mutations in human cancers
Vinagre, J., Almeida, A., Pópulo, H., Batista, R., Lyra, J., Pinto, V., Coelho, R., Celestino, R., Prazeres, H., Lima, L., et al. (2013) · Nature Communications · doi:10.1038/ncomms3185 · Cited by 898
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
Linardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C. A., & Murray, S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70206-7 · Cited by 739
Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., Rougier, P., Lievre, A., Landi, B., Boige, V., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6796 · Cited by 673
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Bardelli, A., Corso, S., Bertotti, A., Hobor, S., Valtorta, E., Siravegna, G., Sartore-Bianchi, A., Scala, E., Cassingena, A., Zecchin, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0558 · Cited by 657
Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30904-5 · Cited by 573
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
Frattini, M., Saletti, P., Romagnani, E., Martin, V, Molinari, F., Ghisletta, M., Camponovo, A., Etienne, L. L., Cavalli, F., & Mazzucchelli, L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604009 · Cited by 540
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0462 · Cited by 513
Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer
Carethers, J. M., & Jung, B. H. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.06.047 · Cited by 483
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479
Self-citationJhawer, M., Goel, S., Wilson, A. J., Montagna, C., Ling, Y.-H., Byun, D.-S., Nasser, S., Arango, D., Shin, J., Klampfer, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5659 · Cited by 460
Cremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5080 · Cited by 424
Perrone, F., Lampis, A., Orsenigo, M., Di Bartolomeo, M., Gevorgyan, A., Losa, M., Frattini, M., Riva, C., Andreola, S., Bajetta, E., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn541 · Cited by 410
Loupakis, F., Pollina, L., Stasi, I., Ruzzo, A., Scartozzi, M., Santini, D., Masi, G., Graziano, F., Cremolini, C., Rulli, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2796 · Cited by 403
Chen, P., Li, X., Zhang, R., Liu, S., Xiang, Y., Zhang, M., Chen, X., Pan, T., Yan, L., Feng, J., et al. (2020) · Theranostics · doi:10.7150/thno.44705 · Cited by 403
Jacobs, B., De Roock, W., Piessevaux, H., Van Oirbeek, R., Biesmans, B., De Schutter, J., Fieuws, S., Vandesompele, J., Peeters, M., Van Laethem, J.-L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3744 · Cited by 368
Tabernero, J., Van Cutsem, E., Díaz-Rubio, E., Cervantes, A., Humblet, Y., André, T., Van Laethem, J.-L., Soulié, P., Casado, E., Verslype, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.2183 · Cited by 337
Wu, Y.-L., Zhang, L., Kim, D.-W., Liu, X., Lee, D. H., Yang, J. C.-H., Ahn, M.-J., Vansteenkiste, J. F., Su, W.-C., Felip, E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.7326 · Cited by 333
Innocenti, F., Ou, F.-S., Qu, X., Zemla, T. J., Niedzwiecki, D., Tam, R., Mahajan, S., Goldberg, R. M., Bertagnolli, M. M., Blanke, C. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01798 · Cited by 317
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., Searleman, A. C., Shen, W., Monsey, J., Trusolino, L., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1211 · Cited by 302
BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives
Sanz-Garcia, E., Argiles, G., Elez, E., & Tabernero, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx401 · Cited by 302
Yaeger, R., Cercek, A., O'Reilly, E. M., Reidy, D. L., Kemeny, N., Wolinsky, T., Capanu, M., Gollub, M. J., Rosen, N., Berger, M. F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2779 · Cited by 276
The Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272
Misale, S., Arena, S., Lamba, S., Siravegna, G., Lallo, A., Hobor, S., Russo, M., Buscarino, M., Lazzari, L., Sartore-Bianchi, A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007947 · Cited by 263
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
Bokemeyer, C., Köhne, C.-H., Ciardiello, F., Lenz, H.-J., Heinemann, V., Klinkhardt, U., Beier, F., Duecker, K., van Krieken, J. H., & Tejpar, S. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.04.007 · Cited by 256
Woolston, A., Khan, K., Spain, G., Barber, L. J., Griffiths, B., Gonzalez-Exposito, R., Hornsteiner, L., Punta, M., Patil, Y., Newey, A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.013 · Cited by 254
EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma
Messa, C., Russo, F., Gabriella Caruso, M., & Di Leo, A. (1998) · Acta Oncologica · doi:10.1080/028418698429595 · Cited by 251
Molecular determinants of cetuximab efficacy.
Vallböhmer, D., Zhang, W., Gordon, M., Yang, D. Y., Yun, J., Press, O. A., Rhodes, K. E., Sherrod, A. E., Iqbal, S., Danenberg, K. D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.100 · Cited by 234
Martinelli, E., Ciardiello, D., Martini, G., Troiani, T., Cardone, C., Vitiello, P. P., Normanno, N., Rachiglio, A. M., Maiello, E., Latiano, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.007 · Cited by 225
Van Cutsem, E., Huijberts, S., Grothey, A., Yaeger, R., Cuyle, P.-J., Elez, E., Fakih, M., Montagut, C., Peeters, M., Yoshino, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02459 · Cited by 224
Hong, D. S., Morris, V. K., El Osta, B., Sorokin, A. V., Janku, F., Fu, S., Overman, M. J., Piha-Paul, S., Subbiah, V., Kee, B., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0050 · Cited by 219
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Van Emburgh, B. O., Arena, S., Siravegna, G., Lazzari, L., Crisafulli, G., Corti, G., Mussolin, B., Baldi, F., Buscarino, M., Bartolini, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13665 · Cited by 214
Mimeault, M., Hauke, R., Mehta, P. P., & Batra, S. K. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00088.x · Cited by 212
Mao, C., Yang, Z. Y., Hu, X. F., Chen, Q., & Tang, J. L. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr464 · Cited by 188
Li, X., & Fan, Z. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0157 · Cited by 179
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
Cappuzzo, F., Varella-Garcia, M., Finocchiaro, G., Skokan, M., Gajapathy, S., Carnaghi, C., Rimassa, L., Rossi, E., Ligorio, C., Di Tommaso, L., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604439 · Cited by 178
HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation
Liska, D., Chen, C.-T., Bachleitner-Hofmann, T., Christensen, J. G., & Weiser, M. R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0568 · Cited by 176
Lutterbuese, R., Raum, T., Kischel, R., Hoffmann, P., Mangold, S., Rattel, B., Friedrich, M., Thomas, O., Lorenczewski, G., Rau, D., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000976107 · Cited by 166
Molinari, F., Felicioni, L., Buscarino, M., De Dosso, S., Buttitta, F., Malatesta, S., Movilia, A., Luoni, M., Boldorini, R., Alabiso, O., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3137 · Cited by 159
Clinicopathological relevance of BRAF mutations in human cancer
Pakneshan, S., Salajegheh, A., Anthony Smith, R., & King-Yin Lam, A. (2013) · Pathology · doi:10.1097/pat.0b013e328360b61d · Cited by 156
PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.
Liao, H.-W., Hsu, J.-M., Xia, W., Wang, H.-L., Wang, Y.-N., Chang, W.-C., Arold, S. T., Chou, C.-K., Tsou, P.-H., Yamaguchi, H., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82826 · Cited by 155
Shapiro, G. I., Rodon, J., Bedell, C., Kwak, E. L., Baselga, J., Braña, I., Pandya, S. S., Scheffold, C., Laird, A. D., Nguyen, L. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1777 · Cited by 152
Troiani, T., Martinelli, E., Napolitano, S., Vitagliano, D., Ciuffreda, L. P., Costantino, S., Morgillo, F., Capasso, A., Sforza, V., Nappi, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0423 · Cited by 150
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.
Luraghi, P., Reato, G., Cipriano, E., Sassi, F., Orzan, F., Bigatto, V., De Bacco, F., Menietti, E., Han, M., Rideout, W. M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2340-t · Cited by 146
Reidy, D. L., Vakiani, E., Fakih, M. G., Saif, M. W., Hecht, J. R., Goodman-Davis, N., Hollywood, E., Shia, J., Schwartz, J., Chandrawansa, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.4154 · Cited by 138
Montagut, C., Argilés, G., Ciardiello, F., Poulsen, T. T., Dienstmann, R., Kragh, M., Kopetz, S., Lindsted, T., Ding, C., Vidal, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5245 · Cited by 135
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133
Borner, M., Koeberle, D., Von Moos, R., Saletti, P., Rauch, D., Hess, V., Trojan, A., Helbling, D., Pestalozzi, B., Caspar, C., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn058 · Cited by 124
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
Misale, S., Bozic, I., Tong, J., Peraza-Penton, A., Lallo, A., Baldi, F., Lin, K. H., Truini, M., Trusolino, L., Bertotti, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9305 · Cited by 122
Molinari, F., Martin, V, Saletti, P., De Dosso, S., Spitale, A., Camponovo, A., Bordoni, A., Crippa, S., Mazzucchelli, L., & Frattini, M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604848 · Cited by 122
Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2887 · Cited by 121
Ciardiello, F., Normanno, N., Maiello, E., Martinelli, E., Troiani, T., Pisconti, S., Giuliani, F., Barone, C., Cartenì, G., Rachiglio, A. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu230 · Cited by 116
Blons, H., Emile, J. F., Le Malicot, K., Julié, C., Zaanan, A., Tabernero, J., Mini, E., Folprecht, G., Van Laethem, J. L., Thaler, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu464 · Cited by 108
Troiani, T., Napolitano, S., Vitagliano, D., Morgillo, F., Capasso, A., Sforza, V., Nappi, A., Ciardiello, D., Ciardiello, F., & Martinelli, E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2181 · Cited by 104
Duldulao, M. P., Lee, W., Nelson, R. A., Li, W., Chen, Z., Kim, J., & Garcia-Aguilar, J. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-2910-0 · Cited by 104
Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations
Lee, J., Lee, I., Han, B., Park, J. O., Jang, J., Park, C., & Kang, W. K. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr070 · Cited by 103
Wang, F., Fu, X., Chen, P., Wu, P., Fan, X., Li, N., Zhu, H. M., Jia, T.-T., Ji, H., Wang, Z., et al. (2017) · Cell Research · doi:10.1038/cr.2017.7 · Cited by 102
Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab
Pander, J., Heusinkveld, M., van der Straaten, T., Jordanova, E. S., Baak-Pablo, R., Gelderblom, H., Morreau, H., van der Burg, S. H., Guchelaar, H.-J., & van Hall, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0239 · Cited by 101
Rocca, Y. S., Roberti, M. P., Juliá, E. P., Pampena, M. B., Bruno, L., Rivero, S., Huertas, E., Sánchez Loria, F., Pairola, A., Caignard, A., et al. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00413 · Cited by 97
Arena, S., Siravegna, G., Mussolin, B., Kearns, J. D., Wolf, B. B., Misale, S., Lazzari, L., Bertotti, A., Trusolino, L., Adjei, A. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad5640 · Cited by 93
Yoon, J., Koo, K.-H., & Choi, K.-Y. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3058 · Cited by 92
Sclafani, F., Kim, T. Y., Cunningham, D., Kim, T. W., Tabernero, J., Schmoll, H. J., Roh, J. K., Kim, S. Y., Park, Y. S., Guren, T. K., et al. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv258 · Cited by 92
Damiano, V., Caputo, R., Bianco, R., D'Armiento, F. P., Leonardi, A., De Placido, S., Bianco, A. R., Agrawal, S., Ciardiello, F., & Tortora, G. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1943 · Cited by 90
Yen, L.-C., Uen, Y.-H., Wu, D.-C., Lu, C.-Y., Yu, F.-J., Wu, I.-C., Lin, S.-R., & Wang, J.-Y. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181bc9d96 · Cited by 89
Ishiguro, N., Moriyama, M., Furusho, K., Furukawa, S., Shibata, T., Murakami, Y., Chinju, A., Haque, A. S. M. R., Gion, Y., Ohta, M., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41052 · Cited by 86
PTEN status in advanced colorectal cancer treated with cetuximab
Negri, F. V., Bozzetti, C., Lagrasta, C. A., Crafa, P., Bonasoni, M. P., Camisa, R., Pedrazzi, G., & Ardizzoni, A. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605471 · Cited by 83
Koustas, E., Karamouzis, M. V., Mihailidou, C., Schizas, D., & Papavassiliou, A. G. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.023 · Cited by 79
Dienstmann, R., Patnaik, A., Garcia-Carbonero, R., Cervantes, A., Benavent, M., Roselló, S., Tops, B. B. J., van der Post, R. S., Argilés, G., Skartved, N. J. Ø., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1432 · Cited by 77
Kloth, M., Ruesseler, V., Engel, C., Koenig, K., Peifer, M., Mariotti, E., Kuenstlinger, H., Florin, A., Rommerscheidt-Fuss, U., Koitzsch, U., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-309026 · Cited by 73
Shin, J. E., Jung, K., Kim, M., Hwang, K., Lee, H.-J., Kim, I., Lee, B. H., Lee, I.-S., & Park, K. I. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0054-9 · Cited by 73
Li, T. X., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00014-6 · Cited by 73
Eng, C., Bessudo, A., Hart, L. L., Severtsev, A., Gladkov, O., Müller, L., Kopp, M. V., Vladimirov, V., Langdon, R., Kotiv, B., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30049 · Cited by 72
Napolitano, S., Martini, G., Rinaldi, B., Martinelli, E., Donniacuo, M., Berrino, L., Vitagliano, D., Morgillo, F., Barra, G., De Palma, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0020 · Cited by 72
Damiano, V., Caputo, R., Garofalo, S., Bianco, R., Rosa, R., Merola, G., Gelardi, T., Racioppi, L., Fontanini, G., De Placido, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705226104 · Cited by 71
Sánchez-Martín, F. J., Bellosillo, B., Gelabert-Baldrich, M., Dalmases, A., Cañadas, I., Vidal, J., Martinez, A., Argilés, G., Siravegna, G., Arena, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2400 · Cited by 68
Parseghian, C. M., Parikh, N. U., Wu, J. Y., Jiang, Z.-Q., Henderson, L., Tian, F., Pastor, B., Ychou, M., Raghav, K., Dasari, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3138 · Cited by 67
Toll-like receptor 9 antagonizes antibody affinity maturation
Akkaya, M., Akkaya, B., Kim, A. S., Miozzo, P., Sohn, H., Pena, M., Roesler, A. S., Theall, B. P., Henke, T., Kabat, J., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0052-z · Cited by 66
Shinozaki, E., Yoshino, T., Yamazaki, K., Muro, K., Yamaguchi, K., Nishina, T., Yuki, S., Shitara, K., Bando, H., Mimaki, S., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.308 · Cited by 65
Targeting the Colorectal Cancer Stem Cell
Medema, J. P. (2017) · New England Journal of Medicine · doi:10.1056/nejmcibr1706541 · Cited by 63
Resistance to EGFR-Targeted Therapy: A Family Affair
Vlacich, G., & Coffey, R. J. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.006 · Cited by 61
De Angelis, M. L., Zeuner, A., Policicchio, E., Russo, G., Bruselles, A., Signore, M., Vitale, S., De Luca, G., Pilozzi, E., Boe, A., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0214 · Cited by 60
Bagchi, A., Haidar, J. N., Eastman, S. W., Vieth, M., Topper, M., Iacolina, M. D., Walker, J. M., Forest, A., Shen, Y., Novosiadly, R. D., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0575 · Cited by 60
Foster, P., Yamaguchi, K., Hsu, P. P., Qian, F., Du, X., Wu, J., Won, K.-A., Yu, P., Jaeger, C. T., Zhang, W., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0833 · Cited by 58
Du, Z., Liu, X., Chen, T., Gao, W., Wu, Z., Hu, Z., Wei, D., Gao, C., & Li, Q. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.037 · Cited by 56
Self-citationDing, C., Li, L., Yang, T., Fan, X., & Wu, G. (2016) · BMC Cancer · doi:10.1186/s12885-016-2834-8 · Cited by 56
Poindessous, V., Ouaret, D., El Ouadrani, K., Battistella, A., Mégalophonos, V. F., Kamsu-Kom, N., Petitprez, A., Escargueil, A. E., Boudou, P., Dumont, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1607 · Cited by 55
Rosa, R., Melisi, D., Damiano, V., Bianco, R., Garofalo, S., Gelardi, T., Agrawal, S., Di Nicolantonio, F., Scarpa, A., Bardelli, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3376 · Cited by 54
Veluchamy, J. P., Lopez-Lastra, S., Spanholtz, J., Bohme, F., Kok, N., Heideman, D. A. M., Verheul, H. M. W., Di Santo, J. P., de Gruijl, T. D., & van der Vliet, H. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00087 · Cited by 54
Deming, D. A., Cavalcante, L. L., Lubner, S. J., Mulkerin, D. L., LoConte, N. K., Eickhoff, J. C., Kolesar, J. M., Fioravanti, S., Greten, T. F., Compton, K., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-015-0314-7 · Cited by 52
Rimassa, L., Bozzarelli, S., Pietrantonio, F., Cordio, S., Lonardi, S., Toppo, L., Zaniboni, A., Bordonaro, R., Di Bartolomeo, M., Tomasello, G., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.02.004 · Cited by 50
Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer
Cohen, A. S., Geng, L., Zhao, P., Fu, A., Schulte, M. L., Graves-Deal, R., Washington, M. K., Berlin, J., Coffey, R. J., & Manning, H. C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100828 · Cited by 49
Jung, S.-A., Lee, D.-H., Moon, J.-H., Hong, S.-W., Shin, J.-S., Hwang, I. Y., Shin, Y. J., Kim, J. H., Gong, E.-Y., Kim, S.-M., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.03.009 · Cited by 47
Calemma, R., Ottaiano, A., Trotta, A. M., Nasti, G., Romano, C., Napolitano, M., Galati, D., Borrelli, P., Zanotta, S., Cassata, A., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-232 · Cited by 47
Oliveras‐Ferraros, C., Vazquez‐Martin, A., Cufí, S., Queralt, B., Báez, L., Guardeño, R., Hernández‐Yagüe, X., Martin‐Castillo, B., Brunet, J., & Menendez, J. A. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22952 · Cited by 47
Jutten, B., Keulers, T. G., Peeters, H. J. M., Schaaf, M. B. E., Savelkouls, K. G. M., Compter, I., Clarijs, R., Schijns, O. E. M. G., Ackermans, L. P. C. M., Teernstra, O., et al. (2018) · Autophagy · doi:10.1080/15548627.2017.1409926 · Cited by 47
Winder, T., Zhang, W., Yang, D., Ning, Y., Bohanes, P., Gerger, A., Wilson, P. M., Pohl, A., Mauro, D. J., Langer, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2092 · Cited by 46
Bowles, D. W., Kochenderfer, M., Cohn, A., Sideris, L., Nguyen, N., Cline-Burkhardt, V., Schnadig, I., Choi, M., Nabell, L., Chaudhry, A., et al. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.03.004 · Cited by 42
Colorectal cancer cells are resistant to anti-EGFR monoclonal antibody through adapted autophagy.
Chen, Z., Gao, S., Wang, D., Song, D., & Ye, F. (2016) · PubMed · Cited by 42
Kuwada, S. K., Scaife, C. L., Kuang, J., Li, X., Wong, R. F., Florell, S. R., Coffey, R. J., & Gray, P. D. (2004) · International Journal of Cancer · doi:10.1002/ijc.11686 · Cited by 41
Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab
Bellier, J., Nokin, M.-J., Caprasse, M., Tiamiou, A., Blomme, A., Scheijen, J. L., Koopmansch, B., MacKay, G. M., Chiavarina, B., Costanza, B., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.012 · Cited by 38
Maddalena, F., Condelli, V., Matassa, D. S., Pacelli, C., Scrima, R., Lettini, G., Li Bergolis, V., Pietrafesa, M., Crispo, F., Piscazzi, A., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12814 · Cited by 38
Cuneo, K. C., Mehta, R. K., Kurapati, H., Thomas, D. G., Lawrence, T. S., & Nyati, M. K. (2019) · Translational Oncology · doi:10.1016/j.tranon.2018.10.005 · Cited by 38
Vincenzi, B., Santini, D., Russo, A., Gavasci, M., Battistoni, F., Dicuonzo, G., Rocci, L., Rosaria, V. M., Gebbia, N., & Tonini, G. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.4.319 · Cited by 38
Lim, Y., Yoo, J., Kim, M.-S., Hur, M., Lee, E. H., Hur, H.-S., Lee, J.-C., Lee, S.-N., Park, T. W., Lee, K., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0679 · Cited by 38
Targeting the PI 3K signaling pathway in KRAS mutant colon cancer
Hong, S., Kim, S., Kim, H. Y., Kang, M., Jang, H. H., & Lee, W. (2016) · Cancer Medicine · doi:10.1002/cam4.591 · Cited by 37
Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells
Song, N., Liu, S., Zhang, J., Liu, J., Xu, L., Liu, Y., & Qu, X. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15045838 · Cited by 37
Ciardiello, F., & Normanno, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0261 · Cited by 36
Okada, J., Matsumoto, S., Kaira, K., Saito, T., Yamada, E., Yokoo, H., Katoh, R., Kusano, M., Okada, S., & Yamada, M. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.09.005 · Cited by 35
Hong, C., Sun, E., Choi, J., Kim, D., Kim, J., Ryu, K., Shim, H., Hwang, J., Bae, W., Kim, H., et al. (2020) · Cancer Science · doi:10.1111/cas.14526 · Cited by 35
MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Her‐2/PI3K/AKT Signaling
Han, Y., Peng, Y., Fu, Y., Cai, C., Guo, C., Liu, S., Li, Y., Chen, Y., Shen, E., Long, K., et al. (2020) · Advanced Science · doi:10.1002/advs.202000112 · Cited by 34
Mutsaers, A. J., Francia, G., Man, S., Lee, C. R., Ebos, J. M. L., Wu, Y., Witte, L., Berry, S., Moore, M., & Kerbel, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1627 · Cited by 34
Huang, F., Xu, L.-A., & Khambata-Ford, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1135 · Cited by 33
Skvortsov, S., Sarg, B., Loeffler-Ragg, J., Skvortsova, I., Lindner, H., Werner Ott, H., Lukas, P., Illmensee, K., & Zwierzina, H. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1551.3.12 · Cited by 33
Price, T., Ang, A., Boedigheimer, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Satya Suresh, A., Thomas, A., Tjulandin, S., et al. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1798695 · Cited by 33
Sclafani, F., Roy, A., Cunningham, D., Wotherspoon, A., Peckitt, C., Gonzalez de Castro, D., Tabernero, J., Glimelius, B., Cervantes, A., Eltahir, Z., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt408 · Cited by 33
Loupakis, F., Cremolini, C., Fioravanti, A., Orlandi, P., Salvatore, L., Masi, G., Schirripa, M., Di Desidero, T., Antoniotti, C., Canu, B., et al. (2014) · Targeted Oncology · doi:10.1007/s11523-013-0284-7 · Cited by 33
Elez, E., Hendlisz, A., Delaunoit, T., Sastre, J., Cervantes, A., Varea, R., Chao, G., Wallin, J., & Tabernero, J. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.480 · Cited by 33
Subbiah, V., Khawaja, M. R., Hong, D. S., Amini, B., Yungfang, J., Liu, H., Johnson, A., Schrock, A. B., Ali, S. M., Sun, J. X., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90380 · Cited by 30
Kang, I., Lee, B., Lee, J. Y., Kim, J.-J., Sung, E., Lee, S. E., Shin, N., Choi, S. W., Seo, Y., Kim, H., et al. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0176-0 · Cited by 28
Jacobs, S. A., Lee, J. J., George, T. J., Wade, J. L., Stella, P. J., Wang, D., Sama, A. R., Piette, F., Pogue-Geile, K. L., Kim, R. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1831 · Cited by 27
Ye, H., Liu, Y., Wu, K., Luo, H., & Cui, L. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00584-z · Cited by 27
In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells
Luca, T., Barresi, V., Privitera, G., Musso, N., Caruso, M., Condorelli, D. F., & Castorina, S. (2014) · Cell Proliferation · doi:10.1111/cpr.12125 · Cited by 27
Bennouna, J., Deslandres, M., Senellart, H., de Labareyre, C., Ruiz-Soto, R., Wixon, C., Botbyl, J., Suttle, A. B., & Delord, J.-P. (2015) · Investigational New Drugs · doi:10.1007/s10637-014-0142-1 · Cited by 26
Delord, J., Argilés, G., Fayette, J., Wirth, L. J., Kasper, S., Siena, S., Mesía, R., Berardi, R., Cervantes, A. M. R., Dekervel, J., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00928-z · Cited by 25
Gao, L., Xu, J., He, G., Huang, J., Xu, W., Qin, J., Zheng, P., Ji, M., Chang, W., Ren, L., et al. (2019) · PubMed · Cited by 25
Baba, Y., Tamura, T., Satoh, Y., Gotou, M., Sawada, H., Ebara, S., Shibuya, K., Soeda, J., & Nakamura, K. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12074 · Cited by 23
Lee, H., Son, E., Lee, K., Lee, Y., Kim, Y., Lee, J.-C., Lim, Y., Hur, M., Kim, D., & Nam, D.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235894 · Cited by 22
High frequency of activated K‐ras codon 15 mutant in colorectal carcinomas from Taiwanese patients
Wang, J., Hsieh, J., Chen, F., Yeh, C., Alexandersen, K., Huang, T., Chen, D. C. P., & Lin, S. (2003) · International Journal of Cancer · doi:10.1002/ijc.11417 · Cited by 20
Mortara, L., Gariboldi, M. B., Bosi, A., Bregni, M., Pinotti, G., Guasti, L., Squizzato, A., Noonan, D. M., Monti, E., & Campiotti, L. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0586-x · Cited by 18
Troiani, T., Napolitano, S., Martini, G., Martinelli, E., Cardone, C., Normanno, N., Vitagliano, D., Morgillo, F., Fenizia, F., Lambiase, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0211 · Cited by 18
CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies
Houot, R., & Kohrt, H. (2014) · OncoImmunology · doi:10.4161/21624011.2014.941740 · Cited by 15
Schirripa, M., Zhang, W., Heinemann, V., Cao, S., Okazaki, S., Yang, D., Loupakis, F., Berger, M. D., Ning, Y., Miyamoto, Y., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30715 · Cited by 11
Microenvironment plasticity confers cetuximab resistance
Sidaway, P. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0259-4 · Cited by 10
Alonso, V., Escudero, P., Fernández-Martos, C., Salud, A., Méndez, M., Gallego, J., Rodriguez, J.-R., Martín-Richard, M., Fernández-Plana, J., Manzano, H., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.05.004 · Cited by 10
Shin, W., Lee, S.-K., Hwang, J.-H., Park, J.-C., Cho, Y.-H., Ro, E. J., Song, Y., Seo, H. R., & Choi, K.-Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0102-5 · Cited by 10
Berasain, C., & Avila, M. A. (2016) · Hepatology · doi:10.1002/hep.28246 · Cited by 4
Jung, S.-H., Lee, D. H., Moon, J. H., Hong, S. W., Shin, J. S., Hwang, I.-Y., Shin, Y. J., Kim, J. H., Gong, E.-Y., Kim, S. M., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.07.017 · Cited by 4
Antibiotics for whooping cough.
Jenkinson, D. (1980) · BMJ · doi:10.1136/bmj.280.6217.864-d · Cited by 3
Arai, H., Millstein, J., Loupakis, F., Stintzing, S., Wang, J., Battaglin, F., Kawanishi, N., Jayachandran, P., Soni, S., Zhang, W., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.048 · Cited by 2
Cited by
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar, A., Gautam, V., Sandhu, A., Rawat, K., Sharma, A., & Saha, L. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i4.495 · Cited by 272
Menyhárt, O., Fekete, J. T., & Győrffy, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158441 · Cited by 134
“Nevertheless, despite combination therapies, more than half of patients relapse to multidrug-resistant disease [13], and the mortality rate remains relatively high among CRC patients [3].”
BackgroundFerreira, A. I., Pereira, F. D. S., Reis, C. A., Oliveira, M. J., Sousa, M. J., & Preto, A. (2022) · Cells · doi:10.3390/cells11142183 · Cited by 124
Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
Sun, X., Zhao, P., Lin, J., Chen, K., & Shen, J. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.16 · Cited by 96
“Among them, the activating mutations of oncogenes such as EGFR, RAS, RAF, and PI3K are the key driving factors for many cancers([86-89]).”
BackgroundCracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
Du, Y.-F., Karatekin, F., Wang, W. K., Hong, W., & Gandhi, T. K. B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100076 · Cited by 115
Metadata
- Authors
- Zhou, J., Ji, Q., & Li, Q.
- Affiliations
- Shanghai University of Traditional Chinese Medicine (CN)
- Corresponding author
- Ji, Qing
- Li, Qi
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2021-10-18
- Volume
- 40
- Issue
- 1
- Pages
- 328-328
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- PMC
- PMC8522158
- OpenAlex
- W3207379781
- Cited by
- 246
- References
- 156
- Citations by year
- 2026: 53 · 2025: 71 · 2024: 60 · 2023: 38 · 2022: 24
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- national natural science foundation of china (81830120, 82074225)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- metastatic colorectal cancer, anti-EGFR monoclonal antibody, cetuximab, panitumumab, anti-EGFR therapy resistance, metabolic remodeling, microsatellite instability, autophagy, tumor microenvironment, cancer-associated fibroblasts, angiogenesis, immune cells, combination therapy
- MeSH terms
- Clinical Decision-Making, Drug Development, Animals, Antineoplastic Agents, Clinical Trials as Topic, Energy Metabolism, Gene Amplification, Humans, Ligands, Mutation, Neovascularization, Pathologic, Protein Binding, Colorectal Neoplasms, Signal Transduction, Treatment Outcome, Drug Resistance, Neoplasm, Disease Management, Protein Kinase Inhibitors, Microsatellite Instability, Molecular Targeted Therapy, Tumor Microenvironment, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.